Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:ELDN NASDAQ:PALI NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.98-3.4%$3.59$2.61▼$13.99$275.69M1.241.38 million shs221,132 shsELDNEledon Pharmaceuticals$3.83-3.2%$3.25$1.35▼$4.60$294.47M0.941.20 million shs386,687 shsPALIPalisade Bio$1.81-0.3%$1.98$0.53▼$2.86$302.20M1.524.20 million shs749,720 shsPLRXPliant Therapeutics$1.15-1.7%$1.28$1.09▼$1.95$70.90M1.2662,986 shs170,472 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-1.28%-1.28%-21.63%-62.30%ELDNEledon Pharmaceuticals+1.80%+2.33%+23.44%+95.54%+39.58%PALIPalisade Bio-3.21%-9.05%-12.14%+4.62%+159.13%PLRXPliant Therapeutics-0.43%-6.05%-10.38%+4.95%-14.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.98-3.4%$3.59$2.61▼$13.99$275.69M1.241.38 million shs221,132 shsELDNEledon Pharmaceuticals$3.83-3.2%$3.25$1.35▼$4.60$294.47M0.941.20 million shs386,687 shsPALIPalisade Bio$1.81-0.3%$1.98$0.53▼$2.86$302.20M1.524.20 million shs749,720 shsPLRXPliant Therapeutics$1.15-1.7%$1.28$1.09▼$1.95$70.90M1.2662,986 shs170,472 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-1.28%-1.28%-21.63%-62.30%ELDNEledon Pharmaceuticals+1.80%+2.33%+23.44%+95.54%+39.58%PALIPalisade Bio-3.21%-9.05%-12.14%+4.62%+159.13%PLRXPliant Therapeutics-0.43%-6.05%-10.38%+4.95%-14.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33592.64% UpsideELDNEledon Pharmaceuticals 2.40Hold$9.67144.73% UpsidePALIPalisade Bio 2.88Moderate Buy$10.20463.54% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00157.51% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, PALI, ELDN, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026AVXLAnavex Life Sciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.004/22/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/31/2026AVXLAnavex Life Sciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.003/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/23/2026AVXLAnavex Life Sciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.003/13/2026PLRXPliant Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$4.00 ➝ $3.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/APALIPalisade BioN/AN/AN/AN/A$0.73 per shareN/APLRXPliant TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%N/AELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-111.28%-41.82%N/APALIPalisade Bio-$16.78M-$1.43N/AN/AN/AN/A-36.79%-34.34%N/APLRXPliant Therapeutics-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%N/ALatest PLRX, PALI, ELDN, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.16+$0.06-$0.33N/AN/A5/12/2026Q1 2026PALIPalisade Bio-$0.04-$0.05-$0.01-$0.05N/AN/A5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87ELDNEledon PharmaceuticalsN/A7.407.40PALIPalisade BioN/A23.7128.95PLRXPliant TherapeuticsN/A16.8912.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%ELDNEledon Pharmaceuticals56.77%PALIPalisade Bio11.79%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%ELDNEledon Pharmaceuticals12.30%PALIPalisade Bio0.07%PLRXPliant Therapeutics8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.11 millionOptionableELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionablePALIPalisade Bio10167.42 million167.31 millionNot OptionablePLRXPliant Therapeutics9061.92 million56.97 millionOptionablePLRX, PALI, ELDN, and AVXL HeadlinesRecent News About These CompaniesPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street ZenMay 11, 2026 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Reduce" from AnalystsMay 10, 2026 | marketbeat.comPliant Therapeutics (PLRX) Projected to Post Quarterly Earnings on MondayMay 9, 2026 | americanbankingnews.comPliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on MondayMay 6, 2026 | marketbeat.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6, 2026 | globenewswire.comBML Capital Management LLC Buys Shares of 1,546,137 Pliant Therapeutics, Inc. $PLRXMay 6, 2026 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street ZenMay 3, 2026 | marketbeat.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | markets.businessinsider.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | globenewswire.comWall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to SellApril 25, 2026 | marketbeat.comPliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026April 18, 2026 | quiverquant.comQPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingApril 18, 2026 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by AnalystsApril 15, 2026 | marketbeat.comPliant Therapeutics Launches New $50 Million ATM ProgramMarch 30, 2026 | tipranks.comPliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72March 27, 2026 | msn.comPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in ...March 18, 2026 | bakersfield.comBPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingMarch 18, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK)March 14, 2026 | theglobeandmail.comPliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 12, 2026 | finanznachrichten.dePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, PALI, ELDN, and AVXL Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$2.98 -0.11 (-3.41%) As of 10:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Eledon Pharmaceuticals NASDAQ:ELDN$3.82 -0.13 (-3.16%) As of 10:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Palisade Bio NASDAQ:PALI$1.80 -0.01 (-0.28%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Pliant Therapeutics NASDAQ:PLRX$1.14 -0.02 (-1.72%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
